Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CHINA MEDICAL UNIVERSITY

🇹🇼Taiwan

Country: 🇹🇼Taiwan

Ownership: Private

Employees: -

Market Cap: -

Website: http://english.cmu.edu.tw

Clinical Trials

FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Unresectable or Metastatic Colorectal Cancer

Interventions: Drug: FOLFOX/FOLFIRI

First Posted Date: 2023-04-04

Last Posted Date: 2023-04-04

Lead Sponsor: China Medical University, China

Target Recruit Count: 30

Registration Number: NCT05797883

Locations: 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China

Effects of Different Inhalation Oxygen Concentrations on Postoperative Atelectasis

Phase 4

Completed

Conditions: Atelectasis

Interventions: Drug: 30% Oxygen
Drug: 60% Oxygen

First Posted Date: 2022-11-25

Last Posted Date: 2024-07-22

Lead Sponsor: China Medical University, China

Target Recruit Count: 96

Registration Number: NCT05627024

Locations: 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China

Effect of Lithium Carbonate on Postoperative Sleep and Cognitive Function in Patients Undergoing Heart Valve Surgery With Cardiopulmonary Bypass

Phase 4

Recruiting

Conditions: Heart Valve Surgery

Interventions: Drug: Lithium Carbonate 250 MG Oral Tablet
Drug: Calcium Carbonate 500 MG Oral Tablet

First Posted Date: 2022-10-25

Last Posted Date: 2023-07-18

Lead Sponsor: China Medical University, China

Target Recruit Count: 62

Registration Number: NCT05593627

Locations: 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Phase 2

Not yet recruiting

Conditions: Gastrointestinal Tumours
NK-Cell
PD-1 Antibody
DC-Cell

Interventions: Drug: Pembrolizumab
Drug: Nivolumab
Drug: Sintilimab
Drug: Toripalimab
Drug: Camrelizumab
Drug: Tislelizumab
Biological: NK-Cell or DC-Cell

First Posted Date: 2022-07-18

Last Posted Date: 2022-07-18

Lead Sponsor: China Medical University, China

Target Recruit Count: 1

Registration Number: NCT05461235

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Phase 1

Not yet recruiting

Conditions: Regorafenib
Raltitrexed
Colorectal Neoplasms
Third-line Treatment

Interventions: Drug: Regorafenib
Drug: Raltitrexed

First Posted Date: 2022-06-22

Last Posted Date: 2022-06-29

Lead Sponsor: China Medical University, China

Target Recruit Count: 50

Registration Number: NCT05426811

Hemodynamic Management in Women With SHS

Not Applicable

Recruiting

Conditions: Supine Hypotensive Syndrome

First Posted Date: 2022-04-22

Last Posted Date: 2023-03-07

Lead Sponsor: China Medical University, China

Target Recruit Count: 60

Registration Number: NCT05341362

Locations: 🇨🇳
China Medical University, Shenyang, Liaoning, China

Characterizations of Gut Microbiota and Postoperative Sleep in Patients Undergoing Heart Valve Surgery With Cardiopulmonary Bypass

Completed

Conditions: Heart Valve Surgery

First Posted Date: 2021-11-26

Last Posted Date: 2022-10-25

Lead Sponsor: China Medical University, China

Target Recruit Count: 36

Registration Number: NCT05136001

Locations: 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China

the Effect of Trans-nasal Fixation of Endotracheal Tubes for Prone Ventilation

Not Applicable

Completed

Conditions: Prone Craniotomy
Endotracheal Intubation Fixation

First Posted Date: 2021-10-26

Last Posted Date: 2022-03-08

Lead Sponsor: China Medical University, China

Target Recruit Count: 30

Registration Number: NCT05093595

Locations: 🇨🇳
Yue Yun, Shenyang, Liaoning, China

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Sintilimab

First Posted Date: 2020-11-03

Last Posted Date: 2020-11-03

Lead Sponsor: China Medical University, China

Target Recruit Count: 33

Registration Number: NCT04612673

Locations: 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index

Not Applicable

Completed

Conditions: Electroencephalography
Anesthesia Monitor
Sleep

First Posted Date: 2020-09-24

Last Posted Date: 2021-11-09

Lead Sponsor: China Medical University, China

Target Recruit Count: 30

Registration Number: NCT04562181

Locations: 🇨🇳
Wen-fei Tan, Shenyang, Liaoning, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy